Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For resected primary tumor participants, and participants with primary tumor in situ:
Previously untreated metastatic colorectal cancer and not a candidate for curative resection
World Health Organization (WHO) performance status of 0-1
Life expectancy of greater than or equal to (\>/=) 3 months
Eligible for XELOX, mFOLFOX6, FOLFIRI and bevacizumab treatment in accordance with local standards of care and pharmaceutical benefits scheme guidelines
Intact primary tumor of the colon or the rectum not requiring surgical intervention prior to study start
Minimal or asymptomatic primary tumor
Presence of active inflammatory bowel disease
History of gastrointestinal perforations
Peritoneal disease
History of significant bleeding event
Significant vascular disease
Peripheral arterial thrombosis or other thrombotic event within 6 months before study start
You may not be if
Resected primary tumor participants, and participants with primary tumor in situ:
Previous chemotherapy for metastatic colorectal cancer
Previous neoadjuvant or adjuvant chemotherapy less than 6 months prior to study start
Radiotherapy within 28 days prior to enrollment or not recovered from a radiotherapy
Prior endoscopic management of the current tumor
Acute diverticulitis
Presence of intra-abdominal abscess
Active gastroduodenal ulcer
Clareo Health | A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
